IP Library › Granted Patent US 12,338,464
Granted Patent B2
US 12,338,464 · App. 17/466,381 · Granted Jun 24, 2025

Clonal strains of attenuated vaccinia viruses and methods of use thereof

Inventors: Aladar A. Szalay (Highland, CA); Nanhai G. Chen (San Diego, CA); Yong A. Yu (San Diego, CA); Qian Zhang (San Diego, CA)
Assignee: Genelux Corporation
C12N7/00A61K35/768C07K16/22C07K2317/622C12N2710/24121C12N2710/24132C12N2710/24143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,338,464
App. No.
17/466,381
Granted
Jun 24, 2025
Kind
B2
Abstract

Clonal strains of vaccinia viruses are provided. Also provided are methods of identifying and isolating attenuated and oncolytic clonal strains from virus preparations. Modified recombinant forms of the clonal strains also are provided. The clonal strains and virus preparations can be used for diagnostic and therapeutic methods, in particular for therapy and diagnosis or monitoring treatment of proliferative disorders, including neoplastic diseases, such as, but are not limited to, solid tumors and blood cancers.

Claims (147)

1. An isolated clonal LIVP strain, wherein:

the genome of the clonal LIVP strain is not modified to contain non-viral heterologous nucleic acid containing an open reading frame encoding a non-viral heterologous protein;

the genome of the clonal strain comprises the sequence of nucleotides selected from among:

a) nucleotides 2,256-181,114 of SEQ ID NO:1, nucleotides 11,243-182,721 of SEQ ID NO:2, nucleotides 6,264-181,390 of SEQ ID NO:4, nucleotides 7,044-181,820 of SEQ ID NO:5, nucleotides 6,674-181,409 of SEQ ID NO:6, nucleotides 6,716-181,367 of SEQ ID NO:7, or nucleotides 6,899-181,870 of SEQ ID NO:8; and

b) a sequence of nucleotides that has at least 95% sequence identity to the sequence of nucleotides 2,256-181,114 of SEQ ID NO:1, nucleotides 11,243-182,721 of SEQ ID NO:2, nucleotides 6,264-181,390 of SEQ ID NO:4, nucleotides 7,044-181,820 of SEQ ID NO:5, nucleotides 6,674-181,409 of SEQ ID NO:6, nucleotides 6,716-181,367 of SEQ ID NO:7, or nucleotides 6,899-181,870 of SEQ ID NO:8;

the clonal LIVP strain has greater anti-tumorigenicity or reduced toxicity or both compared to the strain designated GLV-1h68;

the genome of the clonal LIVP strain comprises a sequence of nucleotides that has at least 90% sequence identity with the sequence of nucleotides set forth in SEQ ID NO: 10 but does not comprise the sequence of nucleotides set forth in SEQ ID NO:10; and

the isolated clonal strain is produced by or obtainable by a method comprising:

(i) preparing a clonal isolate from an LIVP virus sample;

(ii) assaying the clonal isolate for toxicity;

(iii) assaying the clonal isolate for anti-tumorigenicity; and

(iv) selecting the clonal isolate that exhibits greater anti-tumorigenicity and/or reduced toxicity compared to GLV-1h68.

2. The isolated strain of claim 1 , wherein the genome of the clonal LIVP strain comprises a sequence of nucleotides that has at least 95% sequence identity with the sequence of nucleotides set forth in SEQ ID NO: 10 but does not comprise the sequence of nucleotides set forth in SEQ ID NO: 10.

3. A composition, comprising the isolated strain of claim 1 .

4. An isolated clonal LIVP strain, wherein the genome of the clonal LIVP strain comprises the sequence of nucleotides set forth in any of SEQ ID NOS: 1, 2, 4, 5, 6, 7 and 8 or a sequence having at least 99% sequence identity to the sequence of nucleotides set forth in any of SEQ ID NOS: 1, 2, 4, 5, 6, 7 and 8.

5. The isolated clonal strain of claim 1 , wherein the clonal strain has reduced toxicity compared to the virus designated GLV-1h68.

6. The isolated clonal strain of claim 1 , wherein the clonal strain has greater anti-tumorigenicity compared to the virus strain designated GLV-1h68.

7. The isolated clonal strain of claim 1 , wherein the clonal strain has reduced toxicity and greater anti-tumorigenicity compared to the virus designated GLV-1h68.

8. An isolated clonal LIVP strain, wherein:

the genome of the clonal strain comprises the sequence of nucleotides selected from among:

a) nucleotides 2,256-181,114 of SEQ ID NO:1, nucleotides 11,243-182,721 of SEQ ID NO:2, nucleotides 6,264-181,390 of SEQ ID NO:4, nucleotides 7,044-181,820 of SEQ ID NO:5, nucleotides 6,674-181,409 of SEQ ID NO:6, nucleotides 6,716-181,367 of SEQ ID NO:7, or nucleotides 6,899-181,870 of SEQ ID NO:8; and

b) a sequence of nucleotides that has at least 95% sequence identity to the sequence of nucleotides 2,256-181,114 of SEQ ID NO:1, nucleotides 11,243-182,721 of SEQ ID NO:2, nucleotides 6,264-181,390 of SEQ ID NO:4, nucleotides 7,044-181,820 of SEQ ID NO:5, nucleotides 6,674-181,409 of SEQ ID NO:6, nucleotides 6,716-181,367 of SEQ ID NO:7, or nucleotides 6,899-181,870 of SEQ ID NO:8; and

the clonal strain has greater anti-tumorigenicity and/or reduced toxicity compared to GLV-1h68.

9. The isolated clonal strain of claim 8 , wherein the genome of the clonal strain consists of the sequence of nucleotides selected from among:

a) nucleotides 1 to 183,369 of SEQ ID NO:1, nucleotides 1-193,964 of SEQ ID NO:2, nucleotides 1-187,653 of SEQ ID NO:4, nucleotides 1-188,863 of SEQ ID NO:5, nucleotides 1-188,082 of SEQ ID NO:6, nucleotides 1-188,082 of SEQ ID NO:7, or nucleotides 1-188,768 of SEQ ID NO:8; and

b) a sequence of nucleotides that has at least 95% sequence identity to the sequence of nucleotides 1 to 183,369 of SEQ ID NO: 1, nucleotides 1-193,964 of SEQ ID NO:2, nucleotides 1-187,653 of SEQ ID NO:4, nucleotides 1-188,863 of SEQ ID NO:5, nucleotides 1-188,082 of SEQ ID NO:6, nucleotides 1-188,082 of SEQ ID NO:7, or nucleotides 1-188,768 of SEQ ID NO:8.

10. A cell culture or isolated cell, comprising a clonal LIVP strain, wherein:

the genome of the clonal LIVP does not contain non-viral heterologous nucleic acid containing an open reading frame encoding a non-viral heterologous protein;

the clonal LIVP strain has greater anti-tumorigenicity or reduced toxicity or both compared to GLV-1h68;

the genome of the clonal LIVP strain comprises a sequence of nucleotides that has at least 90% sequence identity with the sequence of nucleotides set forth in SEQ ID NO: 10 but does not comprise the sequence of nucleotides set forth in SEQ ID NO:10;

the isolated clonal strain is produced by or obtainable by a method comprising:

(i) preparing a clonal isolate from an LIVP virus sample;

(ii) assaying the clonal isolate for toxicity;

(iii) assaying the clonal isolate for anti-tumorigenicity; and

(iv) selecting the clonal isolate that exhibits greater anti-tumorigenicity and/or reduced toxicity compared to GLV-1h68; and

the clonal LIVP strain is selected from among:

a) the clonal LIVP strain designated LIVP 1.1.1, wherein the clonal strain comprises the sequence of nucleotides 2,256-181,114 of SEQ ID NO:1;

b) the clonal LIVP strain designated LIVP 2.1.1, wherein the clonal strain comprises the sequence of nucleotides 11,243-182,721 of SEQ ID NO:2;

c) the clonal LIVP strain designated LIVP 4.1.1, wherein the clonal strain comprises the sequence of nucleotides 6,264-181,390 of SEQ ID NO:4;

d) the clonal LIVP strain designated LIVP 5.1.1, wherein the clonal strain comprises the sequence of nucleotides 7,044-181,820 of SEQ ID NO:5;

e) the clonal LIVP strain designated LIVP 6.1.1, wherein the clonal strain comprises the sequence of nucleotides 6,674-181,409 of SEQ ID NO:6;

f) the clonal LIVP strain designated LIVP 7.1.1, wherein the clonal strain comprises the sequence of nucleotides 6,716-181,367 of SEQ ID NO:7;

g) the clonal LIVP strain designated LIVP 8.1.1, wherein the clonal strain comprises the sequence of nucleotides 6,899-181,870 of SEQ ID NO:8;

h) a clonal LIVP strain that comprises a sequence of nucleotides that has at least 95% sequence identity to the sequence of nucleotides 2,256-181,114 of SEQ ID NO:1;

i) a clonal LIVP strain that comprises a sequence of nucleotides that has at least 95% sequence identity to the sequence of nucleotides 11,243-182,721 of SEQ ID NO:2;

j) a clonal LIVP strain that comprises a sequence of nucleotides that has at least 95% sequence identity to the sequence of nucleotides 6,264-181,390 of SEQ ID NO:4;

k) a clonal LIVP strain that comprises a sequence of nucleotides that has at least 95% sequence identity to the sequence of nucleotides 7,044-181,820 of SEQ ID NO:5;

l) A clonal LIVP strain that comprises a sequence of nucleotides that has at least 95% sequence identity to the sequence of nucleotides 6,674-181,409 of SEQ ID NO:6;

m) a clonal LIVP strain that comprises a sequence of nucleotides that has at least 95% sequence identity to the sequence of nucleotides 6,716-181,367 of SEQ ID NO:7; and

n) a clonal LIVP strain that comprises a sequence of nucleotides that has at least 95% sequence identity to the sequence of nucleotides 6,899-181,870 of SEQ ID NO:8.

11. An isolated clonal strain produced by:

propagating the cell or cell culture of claim 10 ;

testing clones for greater anti-tumorigenicity or reduced toxicity compared to GLV-1h68;

selecting a clone from the propagated cell or cell culture that has greater anti-tumorigenicity or reduced toxicity or both compared to GLV-1h68; and

isolating the selected clone.

12. A recombinant LIVP virus strain that is a derivative of a clonal LIVP strain, comprising deletion of nucleic acid or replacement of nucleic acid with heterologous nucleic acid or insertion of heterologous nucleic acid in the genome of the clonal LIVP strain, whereby the recombinant strain retains the ability to replicate, but is modified in its genomic sequence compared to the genome of the clonal LIVP strain, wherein:

the recombinant LIVP virus strain has greater anti-tumorigenicity or reduced toxicity or both compared to GLV-1h68;

the genome of the clonal LIVP strain does not contain non-viral heterologous nucleic acid containing an open reading frame encoding a non-viral heterologous protein;

the clonal LIVP strain has greater anti-tumorigenicity or reduced toxicity or both compared to GLV-1h68;

the genome of the clonal LIVP strain comprises a sequence of nucleotides that has at least 90% sequence identity with the sequence of nucleotides set forth in SEQ ID NO:10 but does not comprise the sequence of nucleotides set forth in SEQ ID NO:10;

the isolated clonal strain is produced by or obtainable by a method comprising:

(i) preparing a clonal isolate from an LIVP virus sample;

(ii) assaying the clonal isolate for toxicity;

(iii) assaying the clonal isolate for anti-tumorigenicity; and

(iv) selecting the clonal isolate that exhibits greater anti-tumorigenicity or reduced toxicity or both compared to GLV-1h68; and

the clonal LIVP strain is selected from among:

a) the clonal LIVP strain designated LIVP 1.1.1, wherein the clonal strain comprises the sequence of nucleotides 2,256-181,114 of SEQ ID NO:1;

b) the clonal LIVP strain designated LIVP 2.1.1, wherein the clonal strain comprises the sequence of nucleotides 11,243-182,721 of SEQ ID NO:2;

c) the clonal LIVP strain designated LIVP 4.1.1, wherein the clonal strain comprises the sequence of nucleotides 6,264-181,390 of SEQ ID NO:4;

d) the clonal LIVP strain designated LIVP 5.1.1, wherein the clonal strain comprises the sequence of nucleotides 7,044-181,820 of SEQ ID NO:5;

e) the clonal LIVP strain designated LIVP 6.1.1, wherein the clonal strain comprises the sequence of nucleotides 6,674-181,409 of SEQ ID NO:6;

f) the clonal LIVP strain designated LIVP 7.1.1, wherein the clonal strain comprises the sequence of nucleotides 6,716-181,367 of SEQ ID NO:7;

g) the clonal LIVP strain designated LIVP 8.1.1, wherein the clonal strain comprises the sequence of nucleotides 6,899-181,870 of SEQ ID NO:8;

h) a clonal LIVP strain that comprises a sequence of nucleotides that has at least 95% sequence identity to the sequence of nucleotides 2,256-181,114 of SEQ ID NO:1;

i) a clonal LIVP strain that comprises a sequence of nucleotides that has at least 95% sequence identity to the sequence of nucleotides 11,243-182,721 of SEQ ID NO:2;

j) a clonal LIVP strain that comprises a sequence of nucleotides that has at least 95% sequence identity to the sequence of nucleotides 6,264-181,390 of SEQ ID NO:4;

k) a clonal LIVP strain that comprises a sequence of nucleotides that has at least 95% sequence identity to the sequence of nucleotides 7,044-181,820 of SEQ ID NO:5;

l) A clonal LIVP strain that comprises a sequence of nucleotides that has at least 95% sequence identity to the sequence of nucleotides 6,674-181,409 of SEQ ID NO:6;

m) a clonal LIVP strain that comprises a sequence of nucleotides that has at least 95% sequence identity to the sequence of nucleotides 6,716-181,367 of SEQ ID NO:7; and

n) a clonal LIVP strain that comprises a sequence of nucleotides that has at least 95% sequence identity to the sequence of nucleotides 6,899-181,870 of SEQ ID NO:8.

13. The recombinant LIVP virus strain of claim 12 , wherein the deletion, insertion or replacement is in a non-essential gene or region in the genome of the clonal LIVP virus strain.

14. The recombinant LIVP virus strain of claim 12 , wherein the deletion, insertion or replacement is at the hemagglutinin (HA), thymidine kinase (TK), F14.5L, vaccinia growth factor (VGF), A35R, NIL, E2L/E3L, KIL/K2L, superoxide dismutase, 7.5K, C7-KIL, B13R+B14R, A26L or I4L gene loci in the genome of the clonal LIVP virus strain.

15. The recombinant LIVP virus strain of claim 14 , wherein the heterologous nucleic acid encodes a gene product that is a therapeutic or diagnostic agent.

16. The recombinant LIVP virus strain of claim 14 , wherein the heterologous nucleic acid encodes a gene product that is selected from among an anticancer agent, an antimetastatic agent, an antiangiogenic agent, an immunomodulatory molecule, an antigen, a cell matrix degradative gene product, gene products for tissue regeneration and reprogramming human somatic cells to pluripotency, enzymes that modify a substrate to produce a detectable product or signal or are detectable by antibodies, proteins that can bind a contrasting agent, gene products for optical imaging or detection, gene products for PET imaging and gene products for MRI imaging.

17. The recombinant LIVP virus strain of claim 14 , wherein the heterologous nucleic acid encodes a gene product that is a therapeutic agent selected from among a hormone, a growth factor, a cytokine, a chemokine, a costimulatory molecule, a ribozyme, a transporter protein, a single chain antibody, an antisense RNA, a prodrug converting enzyme, an siRNA, a microRNA, a toxin, an antitumor oligopeptide, a mitosis inhibitor protein, an antimitotic oligopeptide, an anti-cancer polypeptide antibiotic, an angiogenesis inhibitor, a tumor suppressor, a cytotoxic protein, a cytostatic protein and a tissue factor.

18. The recombinant LIVP virus strain of claim 14 , wherein the heterologous nucleic acid encodes a gene product that is a diagnostic agent that is a detectable protein or a protein that induces a detectable signal.

19. The recombinant LIVP virus strain of claim 14 , wherein the heterologous nucleic acid encodes a gene product that is a diagnostic agent selected from among a luciferase, a fluorescent protein, a bioluminescent protein, and a receptor or transporter protein that binds to and/or transports a contrast agent, chromophore, compound or ligand that can be detected.

20. The recombinant LIVP virus strain of claim 14 , wherein the heterologous nucleic acid encodes a gene product that is selected from among a granulocyte macrophage colony stimulating factor (GM-CSF), monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6), interleukin-24 (IL-24), interferon gamma-induced protein 10 (IP-10), lymphotoxin inducible expression competes with HSV glycoprotein D for HVEM a receptor expressed on T-lymphocytes (LIGHT), p60 superantigen, OspF, OspG, signal transducer and activator of transcription protein (STAT1alpha), STAT1beta, plasminogen k5 domain (hK5), pigment epithelium-differentiation factor (PEDF), single chain anti-VEGF antibody, single chain anti-DLL4 antibody, single chain anti-fibroblast activation protein (FAP), NM23, cadherin 1 (ECAD or cdh1), relaxin 1 (RLN1), matrix metallopeptidase 9 (MMP9), erythropoietin (EPO), microRNA 126 (miR-126), microRNA 181, microRNA 335, manganese superoxide dismutase (MnSOD), E3 ubiquitin protein ligase 1 (HACE1), natriuretic peptide precursor A (nppa1), carboxypeptidase G2 (CPG2), alcohol dehydrogenase (ADH), CDC6, bone morphogenetic protein 4 (BMP4), green click beetle luciferase, a lux operon, an infrared fluorescent protein, a flavin reductase protein, mNeptune far-red fluorescent protein, green fluorescent protein (GFP), red fluorescent protein (RFP), coelenterazine-binding protein (CBP), human epinephrine receptor (hNET), a sodium iodide symporter (NIS) protein, a cytochrome p450 family enzyme, allostatin A receptor (AlstR), Pep1 Receptor (PEPR-1), LAT-4, sterol 14 alpha-demethylase (Cyp51), transferrin receptor (TR), ferritin, divalent metal transporter (DMT), Magnetotactic A (MagA), cisplatin influx transporter (CTR1), newt AG (nAG), Oct4, NANOG, Ngn3, Pdx1 and Mafa.

21. The recombinant LIVP virus strain of claim 14 , wherein the heterologous nucleic acid encoding the heterologous gene product is operably linked to a promoter.

22. The recombinant LIVP virus strain of claim 21 , wherein the promoter is a mammalian promoter or a viral promoter.

23. The recombinant LIVP virus strain of claim 21 , wherein the promoter is selected from among P 7.5k , P 11k , P SE , P SEL , P SL , H5R, TK, P28, C11R, G8R, F17R, I3L, I8R, A1L, A2L, A3L, H1L, H3L, H5L, H6R, H8R, D1R, D4R, D5R, D9R, D11L, D12L, D13L, M1L, N2L, P4b and K1 promoters.

24. The recombinant LIVP strain of claim 12 , wherein the genome of the clonal LIVP strain consists of the sequence of nucleotides selected from among:

a) nucleotides 1 to 183,369 of SEQ ID NO:1, nucleotides 1-193,964 of SEQ ID NO:2, nucleotides 1-187,653 of SEQ ID NO:4, nucleotides 1-188,863 of SEQ ID NO:5, nucleotides 1-188,082 of SEQ ID NO:6, nucleotides 1-188,082 of SEQ ID NO:7, or nucleotides 1-188,768 of SEQ ID NO:8; and

b) a sequence of nucleotides that has at least 95% sequence identity to the sequence of nucleotides 1 to 183,369 of SEQ ID NO: 1, nucleotides 1-193,964 of SEQ ID NO:2, nucleotides 1-187,653 of SEQ ID NO:4, nucleotides 1-188,863 of SEQ ID NO:5, nucleotides 1-188,082 of SEQ ID NO:6, nucleotides 1-188,082 of SEQ ID NO:7, or nucleotides 1-188,768 of SEQ ID NO:8.

25. A composition, comprising the recombinant LIVP virus strain of claim 12 .

26. A cell culture or isolated cell, comprising the recombinant LIVP strain of claim 12 .

27. The composition of claim 25 that is a pharmaceutical composition.

28. A method of treating a proliferative disorder in a subject comprising administering a pharmaceutical composition comprising the isolated strain of claim 1 .

29. The method of claim 28 , wherein the proliferative disorder is cancer.

30. The method of claim 29 , wherein the cancer is breast cancer, prostate cancer, ovarian cancer, lung cancer, colon cancer or pancreatic cancer.

31. The method of claim 28 , wherein the subject is a human.

32. The method of claim 28 , wherein the subject is a non-human animal that is selected from among a horse, cat, dog, cow, pig, sheep, goat, mouse, rabbit, chicken, rat, and guinea pig.

33. The method of claim 28 , further comprising another treatment selected from among surgery, radiation therapy, immunosuppressive therapy and administration of an anticancer agent, wherein the further treatment is effected before, after, simultaneously or intermittently with the virus.

34. The method of claim 33 , wherein the further treatment is administration of an anticancer agent selected from among a cytokine, a chemokine, a growth factor, a photosensitizing agent, a toxin, an anti-cancer antibiotic, a chemotherapeutic compound, a radionuclide, an angiogenesis inhibitor, a signaling modulator, an anti-metabolite, an anti-cancer vaccine, an anti-cancer oligopeptide, a mitosis inhibitor protein, an antimitotic oligopeptide, an anticancer antibody, an immunotherapeutic agent, and a combination of any of the preceding thereof.

35. A method of detecting a tumor or metastasis in a subject, comprising:

administering to the subject the clonal strain of claim 18 ; and

detecting the detectable protein or the protein that induces a detectable signal, whereby detection indicates the presence of the tumor or metastasis in the subject.

36. The method of claim 35 , wherein detection is effected by imaging the subject.

37. The method of claim 35 , wherein detection is effected by detecting the protein or signal in a tissue or body fluid sample.

38. The method of claim 35 , wherein the detectable protein or protein that induces a detectable signal is selected from among a luciferase, a fluorescent protein, a bioluminescent protein, and a receptor or transporter protein that binds to and/or transports a contrast agent, chromophore, compound or ligand that can be detected.

39. The method of claim 35 , wherein the detectable protein or detectable signal is detected by low-light imaging, fluorescence spectroscopy, x-ray imaging, magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), positron emission tomography (PET) or single-photon emission computed tomography (SPECT).

40. An LIVP preparation produced by:

propagating the cell or cell culture of claim 10 ;

testing clones for greater anti-tumorigenicity or reduced toxicity compared to GLV-1h68; and

selecting a clone that has one or both of greater anti-tumorigenicity and reduced toxicity compared to GLV-1h68.

41. An LIVP preparation produced by:

propagating the cell or cell culture of claim 26 ;

testing clones for greater anti-tumorigenicity or reduced toxicity compared to GLV-1h68; and

selecting a clone that has one or both of greater anti-tumorigenicity and reduced toxicity compared to GLV-1h68.

42. The recombinant LIVP virus of claim 12 , wherein the heterologous nucleic acid encodes a heterologous gene product.

43. A method of producing a recombinant LIVP virus strain of claim 12 , comprising deleting nucleic acid or replacing nucleic acid with heterologous nucleic acid or inserting heterologous nucleic acid in the genome of the clonal LIVP strain.

44. The method of claim 43 , wherein the deletion, insertion or replacement is in a non-essential gene or region in the genome of the clonal LIVP strain.

45. The method of claim 43 , wherein the heterologous nucleic acid encodes a heterologous gene product.

46. The recombinant LIVP virus strain of claim 12 , wherein the recombinant LIVP virus strain comprises heterologous nucleic acid encoding a gene product selected from among vaccinia virus complement control protein (VCP), DAF/CD55, CD59, MCP/CD46, interleukin-2 (IL-2), interleukin-15 (IL-15) and human sodium iodide symporter (hNIS).

47. The recombinant LIVP virus strain of claim 12 , wherein the recombinant LIVP virus strain comprises heterologous nucleic acid encoding a gene product selected from among interleukin-24 (IL-24), WT1, p53, Pseudomonas A endotoxin, diphtheria toxin, Arf, Bax, HSV TK, Escherichia coli purine nucleoside phosphorylase, angiostatin, endostatin, p16, Rb, BRCA1, cystic fibrosis transmembrane regulator (CFTR), Factor VIII, low density lipoprotein receptor, beta-galactosidase, alpha-galactosidase, beta-glucocerebrosidase, insulin, parathyroid hormone, alpha-1-antitrypsin, rsCD40L, Fas-ligand, TRAIL, TNF, antibodies, microcin E492, Pseudomonas exotoxin, Escherichia coli Shiga toxin, Escherichia coli Verotoxin 1, hyperforin, interleukin-1, interleukin-2, interleukin-6, interleukin-12, tumor necrosis factor alpha (TNF-α), interferon gamma (IFN-γ), granulocyte macrophage colony stimulating factor (GM-CSF), erythropoietin, IL-8, GROα, GROβ, GROγ, ENA-78, LDGF-PBP, GCP-2, PF4, Mig, IP-10, SDF-1α/β, BUNZO/STRC33, I-TAC, BLC/BCA-1, MIP-1α, MIP-1β, MDC, TECK, TARC, RANTES, HCC-1, HCC-4, DC-CK1, MIP-3α, MIP-3β, MCP-1, MCP-2, MCP-3, MCP-4, Eotaxin, Eotaxin-2/MPIF-2, I-309, MIP-5/HCC-2, MPIF-1, 6Ckine, CTACK, MEC, lymphotactin, fractalkine, an anti-VEGF single chain antibody, a plasminogen K5 domain, a human tissue factor-αvβ3-integrin RGD fusion protein, and SIL-6-SIL-6 receptor fusion protein.

48. An isolated clonal strain produced by:

propagating the cell or cell culture of claim 10 ; and

isolating an LIVP clone from the propagated cell or cell culture.

49. A recombinant LIVP strain that is a derivative of a clonal LIVP strain, comprising a deletion of nucleic acid or replacement of nucleic acid with heterologous nucleic acid or insertion of heterologous nucleic acid in the genome of the clonal LIVP strain, whereby the recombinant strain retains the ability to replicate, but is modified in its genomic sequence compared to the genome of the clonal LIVP strain, wherein:

the recombinant LIVP virus strain has greater anti-tumorigenicity or reduced toxicity or both compared to GLV-1h68;

the deletion, insertion or replacement is in a non-essential gene or region in the genome of the clonal LIVP virus strain;

the clonal LIVP strain is selected from among:

a) the clonal LIVP strain designated LIVP 1.1.1, wherein the clonal strain comprises the sequence of nucleotides 2,256-181,114 of SEQ ID NO:1;

b) the clonal LIVP strain designated LIVP 2.1.1, wherein the clonal strain comprises the sequence of nucleotides 11,243-182,721 of SEQ ID NO:2;

c) the clonal LIVP strain designated LIVP 4.1.1, wherein the clonal strain comprises the sequence of nucleotides 6,264-181,390 of SEQ ID NO:4;

d) the clonal LIVP strain designated LIVP 5.1.1, wherein the clonal strain comprises the sequence of nucleotides 7,044-181,820 of SEQ ID NO:5;

e) the clonal LIVP strain designated LIVP 6.1.1, wherein the clonal strain comprises the sequence of nucleotides 6,674-181,409 of SEQ ID NO:6;

f) the clonal LIVP strain designated LIVP 7.1.1, wherein the clonal strain comprises the sequence of nucleotides 6,716-181,367 of SEQ ID NO:7;

g) the clonal LIVP strain designated LIVP 8.1.1, wherein the clonal strain comprises the sequence of nucleotides 6,899-181,870 of SEQ ID NO:8;

h) a clonal LIVP strain that comprises a sequence of nucleotides that has at least 95% sequence identity to the sequence of nucleotides 2,256-181,114 of SEQ ID NO:1;

i) a clonal LIVP strain that comprises a sequence of nucleotides that has at least 95% sequence identity to the sequence of nucleotides 11,243-182,721 of SEQ ID NO:2;

j) a clonal LIVP strain that comprises a sequence of nucleotides that has at least 95% sequence identity to the sequence of nucleotides 6,264-181,390 of SEQ ID NO:4;

k) a clonal LIVP strain that comprises a sequence of nucleotides that has at least 95% sequence identity to the sequence of nucleotides 7,044-181,820 of SEQ ID NO:5;

l) A clonal LIVP strain that comprises a sequence of nucleotides that has at least 95% sequence identity to the sequence of nucleotides 6,674-181,409 of SEQ ID NO:6;

m) a clonal LIVP strain that comprises a sequence of nucleotides that has at least 95% sequence identity to the sequence of nucleotides 6,716-181,367 of SEQ ID NO:7; and

n) a clonal LIVP strain that comprises a sequence of nucleotides that has at least 95% sequence identity to the sequence of nucleotides 6,899-181,870 of SEQ ID NO:8.

50. A method of treating a proliferative disorder in a subject comprising administering a pharmaceutical composition comprising the isolated strain of claim 49 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2021
From: SZALAY, ALADAR A.; CHEN, NANHAI G.; YU, YONG A.; ZHANG, QIAN
To: GENELUX CORPORATION
Reel/Frame 057403/0501 →
Continuity (4)
Continuation 13506369 · Apr 13, 2012
Provisional Application 61628684 · Nov 4, 2011
Provisional Application 61517297 · Apr 15, 2011
Related Publication 20230008052A1 · Jan 12, 2023
References Cited (400)
US 4215051A · Schroeder et al. · 1980 [cited by applicant]
US 4216226A · Fukuyasu et al. · 1980 [cited by applicant]
US 4315914A · Arakawa et al. · 1982 [cited by applicant]
US 4567147A · Ooi et al. · 1986 [cited by applicant]
US 4603112A · Paoletti et al. · 1986 [cited by applicant]
US 4722848A · Paoletti et al. · 1988 [cited by applicant]
US 4769330A · Paoletti et al. · 1988 [cited by applicant]
US 4912199A · Lown et al. · 1990 [cited by applicant]
US 5023252A · Hseih · 1991 [cited by applicant]
US 5110587A · Paoletti et al. · 1992 [cited by applicant]
US 5149653A · Roser · 1992 [cited by applicant]
US 5155020A · Paoletti · 1992 [cited by applicant]
US 5174993A · Paoletti · 1992 [cited by applicant]
US 5179078A · Rollins et al. · 1993 [cited by applicant]
US 5221623A · Legocki et al. · 1993 [cited by applicant]
US 5364773A · Paoletti et al. · 1994 [cited by applicant]
US 5368855A · Boyle et al. · 1994 [cited by applicant]
US 5494807A · Paoletti et al. · 1996 [cited by applicant]
US 5639275A · Baetge et al. · 1997 [cited by applicant]
US 5707928A · Baker · 1998 [cited by applicant]
US 5718902A · Yilma et al. · 1998 [cited by applicant]
US 5719054A · Boursnell et al. · 1998 [cited by applicant]
US 5762938A · Paoletti et al. · 1998 [cited by applicant]
US 5833975A · Paoletti et al. · 1998 [cited by applicant]
US 5861290A · Goldsmith et al. · 1999 [cited by applicant]
US 5866131A · Ramshaw et al. · 1999 [cited by applicant]
US 5922576A · He et al. · 1999 [cited by applicant]
US 5976796A · Szalay et al. · 1999 [cited by applicant]
US 6093700A · Mastrangelo et al. · 2000 [cited by applicant]
US 6165779A · Engler et al. · 2000 [cited by applicant]
US 6190657B1 · Pawelek et al. · 2001 [cited by applicant]
US 6217847B1 · Contag et al. · 2001 [cited by applicant]
US 6232523B1 · Tan et al. · 2001 [cited by applicant]
US 6235967B1 · Tan et al. · 2001 [cited by applicant]
US 6235968B1 · Tan et al. · 2001 [cited by applicant]
US 6251384B1 · Tan et al. · 2001 [cited by applicant]
US 6255289B1 · German et al. · 2001 [cited by applicant]
US 6265183B1 · Dorner et al. · 2001 [cited by applicant]
US 6265189B1 · Paoletti et al. · 2001 [cited by applicant]
US 6319703B1 · Speck · 2001 [cited by applicant]
US 6391579B1 · Carrasco et al. · 2002 [cited by applicant]
US 6416754B1 · Brown et al. · 2002 [cited by applicant]
US 6428968B1 · Molnar-Kimber et al. · 2002 [cited by applicant]
US 6429001B1 · Hardy · 2002 [cited by applicant]
US 6455673B1 · Collier · 2002 [cited by applicant]
US 6491905B1 · Sorscher et al. · 2002 [cited by applicant]
US 6503703B1 · Palese et al. · 2003 [cited by applicant]
US 6537594B1 · Paoletti et al. · 2003 [cited by applicant]
US 6548068B1 · Schlom et al. · 2003 [cited by applicant]
US 6573090B1 · Breakefield et al. · 2003 [cited by applicant]
US 6589531B1 · Andino-Pavlovsky et al. · 2003 [cited by applicant]
US 6649143B1 · Contag et al. · 2003 [cited by applicant]
US 6664099B1 · Worrall · 2003 [cited by applicant]
US 6759038B2 · Tan et al. · 2004 [cited by applicant]
US 6800288B2 · Ferko et al. · 2004 [cited by applicant]
US 6803199B2 · Carrasco et al. · 2004 [cited by applicant]
US 6872357B1 · Bronshtein et al. · 2005 [cited by applicant]
US 6916462B2 · Contag et al. · 2005 [cited by applicant]
US 7045313B1 · Moss et al. · 2006 [cited by applicant]
US 7091030B2 · Setiawan et al. · 2006 [cited by applicant]
US 7115270B2 · Weltzin et al. · 2006 [cited by applicant]
US 7118740B1 · Russell et al. · 2006 [cited by applicant]
US 7550147B2 · Howley et al. · 2009 [cited by applicant]
US 7588767B2 · Szalay et al. · 2009 [cited by applicant]
US 7588771B2 · Szalay et al. · 2009 [cited by applicant]
US 7645456B2 · Weltzin et al. · 2010 [cited by applicant]
US 7662398B2 · Szalay et al. · 2010 [cited by applicant]
US 7754221B2 · Szalay et al. · 2010 [cited by applicant]
US 7763420B2 · Stritzker et al. · 2010 [cited by applicant]
US 7820184B2 · Stritzker et al. · 2010 [cited by applicant]
US 8021662B2 · Szalay et al. · 2011 [cited by applicant]
US 8052968B2 · Chen et al. · 2011 [cited by applicant]
US 8066984B2 · Szalay et al. · 2011 [cited by applicant]
US 8137904B2 · Szalay et al. · 2012 [cited by applicant]
US 8221769B2 · Szalay et al. · 2012 [cited by applicant]
US 8323959B2 · Szalay et al. · 2012 [cited by applicant]
US 8357486B2 · Stritzker et al. · 2013 [cited by applicant]
US 8568707B2 · Szalay et al. · 2013 [cited by applicant]
US 8586022B2 · Szalay et al. · 2013 [cited by applicant]
US 8642257B2 · Szalay et al. · 2014 [cited by applicant]
US 8784836B2 · Szalay et al. · 2014 [cited by applicant]
US 8852927B2 · Szalay et al. · 2014 [cited by applicant]
US 8859256B2 · Szalay et al. · 2014 [cited by applicant]
US 8865153B2 · Szalay et al. · 2014 [cited by applicant]
US 9005602B2 · Szalay et al. · 2015 [cited by applicant]
US 9492534B2 · Szalay et al. · 2016 [cited by applicant]
US 9944903B2 · Szalay et al. · 2018 [cited by applicant]
US 11149254B2 · Szalay et al. · 2021 [cited by applicant]
US 20030009015A1 · Ulrich et al. · 2003 [cited by applicant]
US 20030021768A1 · Shen et al. · 2003 [cited by applicant]
US 20030031628A1 · Zhao et al. · 2003 [cited by applicant]
US 20030031681A1 · McCart et al. · 2003 [cited by applicant]
US 20030044384A1 · Roberts et al. · 2003 [cited by applicant]
US 20030059400A1 · Szalay · 2003 [cited by applicant]
US 20030086906A1 · Mastrangelo et al. · 2003 [cited by applicant]
US 20030153065A1 · Kovesdi et al. · 2003 [cited by applicant]
US 20030198627A1 · Arts et al. · 2003 [cited by applicant]
US 20030228261A1 · Szalay et al. · 2003 [cited by applicant]
US 20030228330A1 · Falkner et al. · 2003 [cited by applicant]
US 20040038410A1 · Setiawan et al. · 2004 [cited by applicant]
US 20040091995A1 · Schlom et al. · 2004 [cited by applicant]
US 20040213741A1 · Szalay et al. · 2004 [cited by applicant]
US 20040234455A1 · Szalay et al. · 2004 [cited by applicant]
US 20050025747A1 · Laidlaw et al. · 2005 [cited by applicant]
US 20050031643A1 · Szalay et al. · 2005 [cited by applicant]
US 20050032044A1 · Sctiwan · 2005 [cited by applicant]
US 20050063993A1 · Schlom et al. · 2005 [cited by applicant]
US 20050069491A1 · Szalay et al. · 2005 [cited by applicant]
US 20050214266A1 · Morris · 2005 [cited by applicant]
US 20050249670A1 · Szalay et al. · 2005 [cited by applicant]
US 20060035857A1 · Clayman · 2006 [cited by applicant]
US 20060051370A1 · Szalay et al. · 2006 [cited by applicant]
US 20060099224A1 · Kirn · 2006 [cited by applicant]
US 20060147420A1 · Fueyo et al. · 2006 [cited by applicant]
US 20060193832A1 · Domann et al. · 2006 [cited by applicant]
US 20070025981A1 · Szalay et al. · 2007 [cited by applicant]
US 20070044164A1 · Dickins et al. · 2007 [cited by applicant]
US 20070086984A1 · Coffey et al. · 2007 [cited by applicant]
US 20070202572A1 · Szalay et al. · 2007 [cited by applicant]
US 20070212727A1 · Szalay et al. · 2007 [cited by applicant]
US 20080193373A1 · Stritzker et al. · 2008 [cited by applicant]
US 20090053244A1 · Chen et al. · 2009 [cited by applicant]
US 20090081639A1 · Hill et al. · 2009 [cited by applicant]
US 20090098529A1 · Chen et al. · 2009 [cited by applicant]
US 20090117034A1 · Chen et al. · 2009 [cited by applicant]
US 20090117047A1 · Szalay et al. · 2009 [cited by applicant]
US 20090117048A1 · Szalay et al. · 2009 [cited by applicant]
US 20090117049A1 · Szalay et al. · 2009 [cited by applicant]
US 20090117082A1 · Lee et al. · 2009 [cited by applicant]
US 20090123382A1 · Szalay et al. · 2009 [cited by applicant]
US 20090136917A1 · Szalay et al. · 2009 [cited by applicant]
US 20090155287A1 · Chen et al. · 2009 [cited by applicant]
US 20090162288A1 · Chen et al. · 2009 [cited by applicant]
US 20090175830A1 · Fueyo et al. · 2009 [cited by applicant]
US 20090180955A1 · Stritzker et al. · 2009 [cited by applicant]
US 20090180987A1 · Stritzker et al. · 2009 [cited by applicant]
US 20090311664A1 · Fong et al. · 2009 [cited by applicant]
US 20090324548A1 · Weltzin et al. · 2009 [cited by applicant]
US 20100008946A1 · Szalay et al. · 2010 [cited by applicant]
US 20100062016A1 · Szalay et al. · 2010 [cited by applicant]
US 20100080775A1 · Perricaudet et al. · 2010 [cited by applicant]
US 20100136658A1 · Hermiston et al. · 2010 [cited by applicant]
US 20100196325A1 · Szalay et al. · 2010 [cited by applicant]
US 20100233078A1 · Szalay et al. · 2010 [cited by applicant]
US 20110293527A1 · Chen · 2011 [cited by applicant]
US 20110300176A1 · Szalay et al. · 2011 [cited by applicant]
US 20120020883A1 · Stritzker et al. · 2012 [cited by applicant]
US 20120052003A9 · Szalay · 2012 [cited by applicant]
US 20120244068A1 · Chen et al. · 2012 [cited by applicant]
US 20120276010A1 · Szalay et al. · 2012 [cited by applicant]
US 20130129614A9 · Szalay et al. · 2013 [cited by applicant]
US 20130130292A1 · Szalay et al. · 2013 [cited by applicant]
US 20130273007A1 · Szalay et al. · 2013 [cited by applicant]
US 20130280170A1 · Szalay · 2013 [cited by applicant]
US 20140086976A1 · Szalay et al. · 2014 [cited by applicant]
US 20140087362A1 · Szalay et al. · 2014 [cited by applicant]
US 20140140959A1 · Szalay et al. · 2014 [cited by applicant]
US 20140271549A1 · Szalay · 2014 [cited by applicant]
US 20140294891A1 · Szalay et al. · 2014 [cited by applicant]
US 20150024403A1 · Szalay et al. · 2015 [cited by applicant]
US 20150175976A1 · Szalay et al. · 2015 [cited by applicant]
US 20160339066A1 · Szalay et al. · 2016 [cited by applicant]
US 20170095552A1 · Szalay et al. · 2017 [cited by applicant]
US 20180195050A1 · Szalay et al. · 2018 [cited by applicant]
US 20190038727A1 · Wood et al. · 2019 [cited by applicant]
CA 2105277 · 2006 [cited by applicant]
CN 1527722A · 2004 [cited by applicant]
CN 1839201A · 2006 [cited by applicant]
EP 0037441 · 1981 [cited by applicant]
EP 0861093 · 1998 [cited by applicant]
EP 1146125 · 2001 [cited by applicant]
EP 1281767 · 2003 [cited by applicant]
EP 1281772 · 2003 [cited by applicant]
EP 1489164 · 2004 [cited by applicant]
EP 1512746 · 2005 [cited by applicant]
EP 1526185 · 2005 [cited by applicant]
JP 2010533718A · 2010 [cited by applicant]
WO WO1992022327 · 1992 [cited by applicant]
WO WO1993001296 · 1993 [cited by applicant]
WO WO1995031105 · 1995 [cited by applicant]
WO WO1999018799 · 1999 [cited by applicant]
WO WO2000073479 · 2000 [cited by applicant]
WO WO2001053467 · 2001 [cited by applicant]
WO WO2003006069 · 2003 [cited by applicant]
WO WO2003014380 · 2003 [cited by applicant]
WO WO2003049117 · 2003 [cited by applicant]
WO WO2004000236 · 2003 [cited by applicant]
WO WO2004014314 · 2004 [cited by applicant]
WO WO2004030631 · 2004 [cited by applicant]
WO WO2005047458 · 2005 [cited by applicant]
WO WO2007030668 · 2007 [cited by applicant]
WO WO2007075879 · 2007 [cited by applicant]
WO WO2008100292 · 2008 [cited by applicant]
WO WO2008113078 · 2008 [cited by applicant]
WO WO2008150496 · 2008 [cited by applicant]
WO WO2008156655 · 2008 [cited by applicant]
WO WO2009011924 · 2009 [cited by applicant]
WO WO2009054996 · 2009 [cited by applicant]
WO WO2009139921 · 2009 [cited by applicant]
WO WO2010031837 · 2010 [cited by applicant]
WO WO2017044780 · 2017 [cited by applicant]
Letter/Written Disclosure of the Information Disclosure Statement for the above-referenced application, filed herewith on Nov. 19, 2021, 3 pages. [cited by applicant]
AACR Press Release, “Virus shows promise for imaging and treating pancreatic cancer,” Published on Sep. 15, 2011 [online] Retrieved Jan. 28, 2013, Retrieved from: <URL:aacr.org/home/public--media/aacr-press-releases.asp… [cited by applicant]
Adonai et al., “Ex vivo cell labeling with [cited by applicant]
Advani et al., “Oncolytic vaccinia virus encoding an anti-VEGF antibody improves the efficacy of fractionated radiotherapy in tumor xenografts,” Poster, ASTRO 53rd Annual Meeting, Miami Beach, FL., Oct. 2-6, 2011, 2 pag… [cited by applicant]
Advani et al., “Oncolytic vaccinia virus encoding an anti-VEGF antibody improves the therapeutic efficacy of fractionated radiotherapy in lung tumor xenografts,” Abstract, ASTRO 53rd Annual Mccting, Miami Beach, FL., Oc… [cited by applicant]
Advani et al., “Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts,” Clin. Cancer Res. 18(9):2579-2590 (2012). [cited by applicant]
Advani et al., “Radiotargeting systemically administered oncolytic vaccinia virus to preferentially replicate in radiated gliomas,” Abstract, ASTRO 53rd Annual Meeting, Miami Beach, FL., Oct. 2-6, 2011, 1 page. [cited by applicant]
Advisory Committee on Immunization Practices (ACIP), “Smallpox vaccination and adverse reactions: guidance for clinicians,” MMWR 52(RR-4):1-29 (2003). [cited by applicant]
Advisory Committee on Immunization Practices (ACIP), “Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP),” MMWR 50(RR-10):1-26 (2001). [cited by applicant]
Agranovski et al., “Rapid detection of airborne viruses by personal bioaerosol sampler combined with the PCR device,” Atmospheric Environment 40:3924-3929 (2006). [cited by applicant]
Ahn et al., “Polarized expression of GABA transporters in Madin-Darby canine kidney cells and cultured hippocampal neurons,” J. Biol. Chem. 271(12):6917-6924 (1996). [cited by applicant]
Akita et al., “Identification of oligopeptides binding to peritoneal tumors of gastric cancer,” Cancer Sci. 97(10):1075-1081 (2006). [cited by applicant]
Alcamí et al., “Vaccinia virus strains Lister, USSR and Evans express soluble and cell-surface tumour necrosis factor receptors,” J. Gen. Virol. 80:949-959 (1999). [cited by applicant]
Al'tshtein et al., “Isolation of a recombinant vaccinia virus based on the LIVP strain inducing a surface antigen of the hepatitis B virus,” Dokl. Akad. Nauk. SSSR 285(3):696-699 (1985) [Article in Russian]. [cited by applicant]
Amato et al., “Luminous with promise,” Chem. Eng. News. 84(49):69-73 (2006). [cited by applicant]
Antoine et al., “Characterization of the vaccinia MVA hemagglutinin gene locus and its evaluation as an insertion site for foreign genes,” Gene 177:43-46 (1996). [cited by applicant]
Arakawa et al., “Clinical trial of attenuated vaccinia virus AS strain in the treatment of advanced adenocarcinoma. Report on two cases,” J. Cancer Res. Clin. Oncol. 113(1):95-98 (1987). [cited by applicant]
Ascierto et al., “Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1H68,” BMC Cancer 11(1):451 (2011). [cited by applicant]
ATCC Accession No. CCL-183, [online] [retrieved on May 7, 2012] Retrieved from: <URL:atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx, 3 pages. [cited by applicant]
ATCC Accession No. VR-1549, [online] [retrieved on Apr. 28, 2010] Retrieved from: <URL:atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx?ATCCNum=VR-1549&Template=animalVirology, 3 pages. [cited by applicant]
ATCC Advanced Catalog Search, Product Details, ATCC No. CCL-107, [cited by applicant]
ATCC Advanced Catalog Search, Product Details, ATCC No. CCL-121, [cited by applicant]
ATCC No. CCL-185, [online] [Retrieved on May 7, 2012] [Retrieved from: <URL:atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx, 3 pages. [cited by applicant]
ATCC No. CCL-70, [online] [Retrieved on May 7, 2012] [Retrieved from: <URL:atcc.org/ATCCAdvancedCatalogScarch/ProductDetails/tabid/452/Default.aspx, 3 pages. [cited by applicant]
ATCC No. CRL-1420, [online] [Rctricved on May 7, 2012] [Retrieved from: <URL:atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx, 3 pages. [cited by applicant]
ATCC No. CRL-1435, [online] [Retrieved on May 7, 2012] [Retrieved from: <URL:atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx?ATCCNum=VR-1549&Template=animalVirology, 3 pages. [cited by applicant]
ATCC No. CRL-1469, [online] [Retrieved on May 7, 2012] [Retrieved from: <URL:atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx?ATCCNum=VR-1549&Template=animalVirology, 3 pages. [cited by applicant]
ATCC No. CRL-6105, [online] [Retrieved on May 7, 2012] [Retrieved from: <URL:atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx, 2 pages. [cited by applicant]
ATCC No. CRL-6475, [online] [Retrieved on Dec. 10, 2004] [Retrieved from: <URL:atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx?ATCCNum=VR-1549&Template=animalVirology, 3 pages. [cited by applicant]
ATCC No. HTB-161, [online] [Retrieved on May 7, 2012] [Retrieved from: <URL:atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx?ATCCNum=VR-1549&Template=animalVirology, 3 pages. [cited by applicant]
ATCC No. HTB-81, [online] [Retrieved on May 7, 2012] [Retrieved from: <URL:atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx?ATCCNum=VR-1549&Template=animalVirology [3 pages]. [cited by applicant]
Ausubel et al., “Generation of recombinant vaccinia viruses,” Unit 16.17 in Short Protocols in Molecular Biology 2 [cited by applicant]
Baroudy et al., “Incompletely base-paired flip-flop terminal loops link the two DNA strands of the vaccinia virus genome into one uninterrupted polynucleotide chain,” Cell 28:315-324 (1982). [cited by applicant]
Barton et al., “GENIS: Gene expression of sodium iodide symporter for noninvasive imaging of gene therapy vectors and quantification of gene expression in vivo”, Mol. Ther. 8:508-518 (2003). [cited by applicant]
Belas et al., “Bacterial bioluminescence: isolation and expression of the luciferase genes from Vibrio harveyi,” Science 218:791-793 (1982). [cited by applicant]
Belin et al., “An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesothelioma,” Surgery 154(3):486-95… [cited by applicant]
Bell et al., “Getting oncolytic virus therapies off the ground,” Cancer Cell 4:7-11 (2003). [cited by applicant]
Bennett et al., “Positron emission tomography imaging for herpes virus infection: implications for oncolytic viral treatments of cancer,” Nature Med. 7(7): 859-863 (2001). [cited by applicant]
Benning, N. and Hasset, D., “Vaccinia virus infection during murine pregnancy: a new pathogenesis model for vaccinia fetalis,” J. Virol. 78(6): 3133-3139 (2004). [cited by applicant]
Bergsland et al., “Shedding old paradigms: developing viruses to treat cancer,” J. Clin. Oncol. 20(9):2220-2222 (2002). [cited by applicant]
Bernards et al., “Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector,” Proc. Natl. Acad. Sci. U.S.A. 84:6854-6858 (1987). [cited by applicant]
Beshara et al., “Kinetic analysis of [cited by applicant]
Bevis, B. and Glick, B., “Rapidly maturing variants of the Discosoma red fluorescent protein (DsRed),” Nat. Biotechnol. 20(1):83-87 (2002). [cited by applicant]
Blasberg et al., “Herpes simplex virus thymidine kinase as a marker/reporter genc for PET imaging of gene therapy,” J. Nucl. Med. 43(2):163-169 (1999). [cited by applicant]
Blasco et al., “Selection of recombinant vaccinia viruses on the basis of plaque formation,” Gene 158:157-162 (1995). [cited by applicant]
Blumenreich et al., “High-dose cisplatin in patients with advanced malignancies,” Cancer 55(5):1118-1122 (1985). [cited by applicant]
Boelaert et al., “Sodium iodide symporter: a novel strategy to target breast, prostate, and other cancers?” Lancet, 361: 796-797 (2003). [cited by applicant]
Boland et al., “Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy,” Cancer Res. 60:3484-3492 (2000). [cited by applicant]
Bonfield et al., “A new DNA sequence assembly program,” Nucl. Acids. Rcs. 23(24): 4992-4999 (1995). [cited by applicant]
Bönisch et al., “The norepinephrine transporter in physiology and disease,” Handb. Exp. Pharmacol. 175:485-524 (2006). [cited by applicant]
Bonnekoh et al., “Adenoviral-mediated herpes simplex virus-thymidine kinase gene transfer in vivo for treatment of experimental human melanoma,” J. Invest. Dermatol. 106(6):1163-1168 (1996). [cited by applicant]
Brader et al., “Imaging genetically engineered oncolytic vaccinia virus (GLV-1h99) using a human norepinephrine transporter reporter gene,” Clin. Cancer Res. 15(11):3791-3801 (2009). [cited by applicant]
Brocks et al., “Species-crossreactive scFv against the tumor stroma marker “fibroblast activation protein” selected by phage display from an immunized FAP -/- knock-out mouse,” Mol. Medicine 7(7):461-469 (2001). [cited by applicant]
Broder et al., “Expression of foreign genes in cultured human primary macrophages using recombinant vaccinia virus vectors,” Gene 142:167-174 (1994). [cited by applicant]
Broder et al., “Recombinant vaccinia viruses,” Mol. Biotechnol. 13:223-245 (1999). [cited by applicant]
Brown, “Killer into cure—oncolytic viruses,” Microbiol. Today 56:128-131 (2005). [cited by applicant]
Browne et al., “Cancer Screening by Systemic Administration of a Gene Delivery Vector Encoding Tumor-Selective Secretable Biomarker Expression,” PLoS One 6(5):e19530 (2011). [cited by applicant]
Broyles, “Vaccinia virus transcription,” J. Gen. Virol. 84:2293-2303 (2003). [cited by applicant]
Broyles, S. and Kremer M., “An in vitro transcription system for studying vaccinia virus early genes,” Methods Mol Biol. 269:135-42 (2004). [cited by applicant]
Buckel et al., “Combination of fractionated irradiation with anti-VEGF expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium,” Int. J. Cancer 133(12)… [cited by applicant]
Buller et al., “Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype,” Nature 317:813-815 (1985). [cited by applicant]
Buller et al., In: “Vaccinia Viruses as Vectors for Vaccine Antigens,” New York: Elsevier, Quinnan, G.V. ed., pp. 37-46 (1985). [cited by applicant]
Buursma et al., “ [cited by applicant]
Calonder et al., “Kinetic modeling of [cited by applicant]
Carlin et al., “In Vitro cytotoxicity of [(211)At]astatide and [131 I]iodide to glioma tumor cells expressing the sodium iodide symporter,” J. Nucl. Med. 44(11):1827-38 (2003). [cited by applicant]
Carlin et al., “Sodium-iodide symporter (NIS)-mediated accumulation of [(211)At]astatide in NIS-transfected human cancer cells,” Nucl. Med. Biol. 29:729-739 (2002). [cited by applicant]
Carrillo et al., “The multiple sequence alignment problem in biology,” SIAM J. Applied Math 48:1073-1082 (1988). [cited by applicant]
Casado et al, “Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications,” Clin. Cancer Res. 7(8):2496-2504 (2001). [cited by applicant]
Certified English translation of Al'tshtein [Altshteyn] et al., “Isolation of a recombinant vaccinia virus based on the LIVP strain inducing a surface antigen of the hepatitis B virus,” Dokl. Akad. Nauk. SSSR. 285(3):69… [cited by applicant]
Certified English Translation of Chernos et al., “Verifying the safety, inoculability, reactogenicity and antigenic properties of a live recombinant smallpox-hepatitis B vaccine in an experiment on volunteers,” Vopr. Vi… [cited by applicant]
Certified English translation of Timiryasova et al., “Analysis of reporter gene expression in various regions of the genome of the vaccinia virus,” Mol. Biol. 27(2):392-401 (1993) [Article in Russian]. [cited by applicant]
Chakrabarti et al., “Compact, synthetic, vaccinia virus early/late promoter for protein expression,” BioTechniques 23(6):1094-1097 (1997). [cited by applicant]
Chakrabarti et al., “Vaccinia virus expression vector: coexpression of β-galactosidase provides visual screening of recombinant virus plaques,” Mol. Cell Biol. 5:3403-3409 (1985). [cited by applicant]
Chalikonda et al., “Chapter 4: Vaccinia and Pox-Virus,” in: Cancer Drug Discovery and Development: Gene Therapy for Cancer, edited by K.K. Hunt et al., Humana Press Inc., Totowa, NJ, pp. 73-85 (2007). [cited by applicant]
Chamberlain et al., “Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines,” Cancer Res. 56:2832-2836 (1996). [cited by applicant]
Cheadle et al., “Bugs as drugs for cancer,” Immunol. 107:10-19 (2002). [cited by applicant]
Chen et al., “Cancer gene therapy by direct tumor injections of a nonviral T7 vector encoding a thymidine kinase gene,” Hum. Gene Ther. 9(5):729-736 (1998). [cited by applicant]
Chen et al., “A novel recombinant vaccinia virus expressing the human norepinephrine transporter retains oncolytic potential and facilitates deep tissue imaging,” Mol. Med. 15(5-6):144-151 (2009). [cited by applicant]
Chen et al., “Oncolytic vaccinia virus: a theranostic agent for cancer,” Future Virology, 5(6):763-784 (2010). [cited by applicant]
Chen et al., “Real-time monitoring of vaccinia virus infection in cultured cells and in living mice using light-emitting proteins,” Proceedings of the 14th International Symposium on Bioluminescence & Chemiluminescence:… [cited by applicant]
Chen et al., “Replication efficiency of oncolytic vaccinia virus in cell cultures prognosticates the virulence and antitumor efficacy in mice,” J. Translational Med. 9(1):164 (2011). [cited by applicant]
Chen et al., “Targeting hematologic malignancies with oncolytic vaccinia virus constructs,” J. Immunother. Cancer. 2013; 1(Suppl. 1): P226. [cited by applicant]
Chen et al., “Tropism of oncolytic vaccinia virus constructs for human mononuclear cell subsets,” 27th Annual Meeting Final Program, Society for Immunotherapy of Cancer (SITC), Oct. 26-28, 2012, North Bethesda, MD. [ora… [cited by applicant]
Chen et al., “Tropism of oncolytic vaccinia virus constructs for human mononuclear cell subsets,” 27th Annual Meeting Final Program, Society for Immunotherapy of Cancer (SITC), Oct. 24-28, 2012, North Bethesda, MD. Pres… [cited by applicant]
Chen et al., “Evaluation of combined vaccinia virus-mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model,” Cancer Gene Ther. 7(11):1437-1447 (2000). [cited by applicant]
Chen et al., “Evaluation of cytokine toxicity induced by vaccinia virus-mediated IL-2 and IL-2 antitumor immunotherapy,” Cytokine 15(61):305-314 (2001). [cited by applicant]
Chernajovsky et al., “Fighting cancer with oncolytic viruses,” BMJ 332(7534):170-172 (2006). [cited by applicant]
Chernichenko et al., “Oncolytic vaccinia therapy of salivary gland carcinoma,” JAMA Otolaryngol. Head Neck Surg. 139(2):173-182 (2013). [cited by applicant]
Chernos et al., “Verifying the safety, inoculability, reactogenicity and antigenic properties of a live recombinant smallpox-hepatitis B vaccine in an experiment on volunteers,” Vopr. Virusol. (Moscow) 35:132-135 (1990)… [cited by applicant]
Chiocca, “Oncolytic viruses,” Nat. Rev. Cancer 2(12):938-950 (2002). [cited by applicant]
Chkheidze et al., “Identification of DNA binding proteins in vaccinia virus by DNA-protein crosslinking,” FEBS 336(2):340-342 (1993). [cited by applicant]
Cho et al., “Expression and activity of human Na+/I-symporter in human glioma cells by adenovirus-mediated gene delivery,” Gene Ther. 7(9):740-749 (2000). [cited by applicant]
Clinicaltrials.gov, “Safety study of GL-ONC1, an oncolytic virus, in patients with advanced solid tumors,” [online] Retrieved Dec. 2, 2008, Retrieved from: <URL:clinicaltrials.gov/ct2/show/NCT00794131?term=genelux&rank=… [cited by applicant]
Condeelis et al., “Intravital imaging of cell movement in tumours,” Nat. Rev. Cancer 3:921-930 (2003). [cited by applicant]
Conry et al., “Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine,” Clin. Cancer Res. 2000, 6:34-41 (2000). [cited by applicant]
Conry et al., “Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration,” Clin. Cancer Res. 5:2330-2337 (… [cited by applicant]
Contag et al., “Photonic detection of bacterial pathogens in living hosts,” Mol. Microbiol. 18:593-603 (1995). [cited by applicant]
Corral et al., “Phase I Clinical Trial of Genetically Modified and Oncolytic Vaccinia Virus GL-ONCl with Green Fluorescent Protein Imaging,” [abstract] 7th NCRI Cancer Conference, Liverpool, UK. Nov. 6-9, 2011. [cited by applicant]
Corral et al., “Phase I Clinical Trial of Genetically Modified and Oncolytic Vaccinia Virus GL-ONCl with Green Fluorescent Protein Imaging,” [poster] 7th NCRI Cancer Conference, Liverpool, UK. Nov. 6-9, 2011. [cited by applicant]
Coupar et al., “A general method for the construction of recombinant vaccinia viruses expressing multiple foreign gencs,” Gene 68:1-10 (1988). [cited by applicant]
Coupar et al., “Insertion sites for recombinant vaccinia virus construction: effects on expression of a foreign protein,” J. Gen. Virol. 81:431-439 (2000). [cited by applicant]
Croyle et al., “Factors that influence stability of recombinant adenoviral preparations for human gene therapy,” Pharm. Dev. Technol. 3(3):373-383 (1998). [cited by applicant]
Davis et al., “Oncolytic virotherapy for cancer treatment: challenges and solutions,” J. Gene Med. 7(11):1380-1389 (2005). [cited by applicant]
Davison et al., “New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins,” Nucleic Acids Res. 18:4285-4286 (1990). [cited by applicant]
Davison et al., “Structure of vaccinia virus early promoters,” J. Mol. Biol. 210:749-769 (1989). [cited by applicant]
Davison, A. and Moss, B., “Structure of vaccinia virus late promoters,” J. Mol. Biol. 210(4):771-784 (1989). [cited by applicant]
De Wet et al., “Firefly luciferase gene: structure and expression in mammalian cells,” Mol. Cell. Biol. 7: 725-737 (1987). [cited by applicant]
Dear et al., “A Sequence assembly and editing program for efficient management of large projects,” Nucleic Acids Res. 19(14):3907-3911 (1991). [cited by applicant]
Dellis et al., “Protein interactions among the vaccinia virus late transcription factors,” Virology 329(2):328-336 (2004). [cited by applicant]
Dingli et al., “Image-guided radiovirotherapy for multiple mycloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter,” Blood 103(5): 1641-1646 (2004). [cited by applicant]
Djikeng et al., “Viral genome sequencing by random priming methods,” BMC Genomics 9:5 (2008). [cited by applicant]
Donat et al., “Preferential colonization of metastases by oncolytic vaccinia virus strain GLV-1h68 in a human PC-3 prostate cancer model in nude mice,” PLOS One 7(9):e45942 (2012). [cited by applicant]
Duggal et al., “Vaccinia virus expressing bone morphogenetic protein-4 in novel glioblastoma orthotopic models facilitates enhanced tumor regression and long-term survival,” J. of Translational Medicine 11:155 (2013). [cited by applicant]
Dunn et al., “Cancer immunoediting: from immunosurveillance to tumor escape,” Nat. Immunol. 3(11):991-998 (2002). [cited by applicant]
Earl et al., “T-lymphocyte priming and protection against friend leukemia by vaccinia-retrovirus env gene recombinant,” Science 234:728-731 (1986). [cited by applicant]
Earl et al., in Ausubel et al. (eds.) Current protocols in molecular biology, vol. 3, pp. 16.17.1-16.19-7 (1998). [cited by applicant]
Ebert et al., “Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer,” Cancer Res. 64:3265-3270 (2004). [cited by applicant]
Ehrig et al, “Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68,” Journal of Translational Medicine 11:79 (2013). [cited by applicant]
Emens, “Cancer vaccines: on the threshold of success,” Expert Opin. Emerg. Drugs 13(2):295-308 (2008). [cited by applicant]
Escher et al., “Bacterial luciferase αβ fusion protein is fully active as a monomer and highly sensitive in vivo to elevated temperature,” Proc. Natl. Acad. Sci. U.S.A. 86(17):6528-6532 (1989). [cited by applicant]
Estin et al, “Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy,” Proc. Natl. Acad. Sci. U.S.A. 85:1052-1056 (1988). [cited by applicant]
Everts et al., “Replication-selective oncolytic viruses in the treatment of cancer,” Cancer Gene Ther. 12:141-161 (2005). [cited by applicant]
Falkner and Moss, “ [cited by applicant]
Falkner and Moss, “Transient dominant selection of recombinant vaccinia viruses,” J. Virol. 64:3108-3111 (1990). [cited by applicant]
Ferrara et al., “Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy,” Biochem. Biophys. Res. Comm. 333:328-335 (2005). [cited by applicant]
Flexner et al., “Characterization of human immunodeficiency virus gag/pol gene products expressed by recombinant vaccinia viruses,” Virol. 166:339-349 (1988). [cited by applicant]
Flint et al., “An oligo-screening strategy to fill gaps found during shotgun sequencing projects,” DNA Seq. 8:241-245 (1998). [cited by applicant]
Fodor et al., “Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model.” J. Urol. 173(2):604-9 (2005). [cited by applicant]
Foran et al., “Nucleotide sequence of the LuxA and LuxB genes of the bioluminescent marine bacterium Vibrio fischeri,” Nucleic Acids Res. 16: 777 (1988). [cited by applicant]
Forastiere et al., “Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology … [cited by applicant]
Frentzen et al., “Anti-VEGF single chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy,” Proc. Natl. Acad. Sci. U.S.A. 106(31):12915-12920 (2009). [cited by applicant]
Frentzen et al., “Usc of GLV-1h68 for Vaccinia Virotherapy and Monitoring,” Genc Therapy of Solid Cancers, Methods in Molecular Biology 1317:225-237 (2015). [cited by applicant]
Galmiche et al., “Expression of a functional single chain antibody on the surface of extracellular enveloped vaccinia virus as a step towards selective tumour cell targeting,” J. Gen. Virol. 78:3019-3027 (1997). [cited by applicant]
Garcel et al., “Genomic sequence of a clonal isolate of the vaccinia virus Lister strain employed for smallpox vaccination in France and its comparison to other orthopoxviruses,” J. Gen. Virol. 88(7):1906-1916 (2007). [cited by applicant]
Gazdar et al., “Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer,” Int. J. Cancer 78:766-774 (1998). [cited by applicant]
Genelux Press Release Feb. 11, 2013, “Virus engineered to express melanin offers new possibilities to diagnose and treat solid tumor cancers,” [online] Retrieved Jul. 3, 2013, Retrieved from: <URL:genelux.com/february-1… [cited by applicant]
Genelux Press Release Feb. 5, 2013, “First Patient Treated in Genelux Phase I trial with GL-ONC1 at Memorial Sloan Kettering Cancer Center,” [online] Retrieved Jul. 3, 2013, Retrieved from: <URL:genclux.com/february-05-… [cited by applicant]
Genelux Press Release Jun. 14, 2012, “Genclux corporation announces first patient doscd in phase I combination clinical trial of GL-ONCI,” [online] Retrieved Jan. 28, 2013, Retrieved from: <URL:genelux.com/genelux2012/?… [cited by applicant]
Genelux Press Release Jun. 15, 2013, “Genelux presents abstracts at the 7th international meeting on replicating oncolytic virus therapeutics in Quebec,” [online] Retrieved Jul. 3, 2013, Retrieved from: <URL:genelux.com… [cited by applicant]
Genelux Press Release Jun. 28, 2012, “Genelux corporation announces ground-breaking clinical study evaluating oncolytic vaccinia virus in canine cancer patients,” [online] Retrieved Jan. 28, 2013, Retrieved from: <URL:g… [cited by applicant]
Genelux Press Release Jun. 6, 2011, “ASCO poster presentation unveils preliminary results of phase I clinical trial involving intravenous administration of GL-ONCI to patients with advanced solid tumor cancers,” [online… [cited by applicant]
Genelux Press Release, “Genelux to present posters supporting lead oncolytic viral therapy GL-ONC1 at ASCO annual meeting 2015,” Published May 12, 2015 [online]; Retrieved Oct. 18, 2017, from: <URL:genelux.com/wp-conten… [cited by applicant]
Genelux Press Release, “Genelux announces promising data from two phase I trials of GL-ONCI in head & neck cancer and mesothelioma,” Published May 27, 2015 [online]; Retrieved Oct. 18, 2017, from: <URL:genelux.com/wp-co… [cited by applicant]
Genelux Press Release May 30, 2012, “Genelux corporation announces phase I data presentation at 2012 ASCO Annual Meeting of GL-ONC1, its oncolytic virus lead product candidate,” [online] Retrieved Jan. 28, 2013, Retriev… [cited by applicant]
Genelux Press Release May 30, 2013, “Genelux corporation presents abstracts at 2013 ASCO annual meeting for clinical trials of GL-ONC1, its oncolytic virus lead product candidate,” [online] Retrieved Jul. 3, 2013, Retri… [cited by applicant]
Genelux Press Release May 31, 2012, “Genelux corporation announces treatment of first patient in phase I/II clinical trial of GL-ONC1 in advanced peritoneal cavity cancers,” [online] Retrieved Jan. 28, 2013, Retrieved f… [cited by applicant]
Genelux Press Release Nov. 1, 2012, “Genelux corporation announces early results of a phase I/II clinical trial of virotherapeutic GL-ONC1 in advanced peritoneal cavity cancers,” [online] Retrieved Jan. 28, 2013, Retrie… [cited by applicant]
Genelux Press Release, “Genelux Initiates Two Clinical Trials of GL-ONCI in Ovarian Cancer and Solid Organ Cancers with Leading Oncology Institutions,” Published Jul. 28, 2016 [online]; Retrieved Jul. 23, 2018, from: <U… [cited by applicant]
Genelux Press Release, “Genelux Initiates Phase 2 Clinical Trial of GL-ONCI in Recurrent Ovarian Cancer,” Published Sep. 27, 2017 [online]; Retrieved Jul. 23, 2018, from: <URL:genelux.com/wp-content/uploads/2012/04/2017… [cited by applicant]
Genelux Press Release, “Genelux Announces Gynecologic Oncology Associates/Women's Cancer Research Foundation as New Site for the Ongoing Phase 2 VIRO-15 Study,” Published Jan. 4, 2018 [online]; Retrieved Jul. 23, 2018, … [cited by applicant]
Genelux Press Release, “Genelux Corporation Announces Productive Type C Meeting with FDA,” Published May 7, 2020 [online]; Retrieved Jun. 24, 2020, from: <URL:prnewswire.com/news-releases/genelux-corporation-announces-p… [cited by applicant]
Gentschev et al., “Characterization and evaluation of a new oncolytic Vaccinia Virus strain LIVP6.1.1 for canine cancer therapy,” Bioengineered 4(2):1-6 (2013). [cited by applicant]
Gentschev et al., “Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68,” PLoS One. 6(7):1-9 (2011). [cited by applicant]
Gentschev et al., “Oncolytic Virotherapy of Canine and Feline Cancer,” Viruses 6:2122-2137 (2014). [cited by applicant]
Gentschev et al., “Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma,” PLoS One 7(5):37239 (2012). [cited by applicant]
Gentschev et al., “Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68,” J. Biomed. Biotechnol. 2010:1-11 (2010). [cited by applicant]
Gentschev et al., “Significant growth inhibition of canine mammary carcinoma xenografts following treatment with oncolytic vaccinia virus GLV-1h68,” J. Oncol. 2010:1-10 (2010). [cited by applicant]
Gentschev et al., “Use of an oncolytic vaccinia virus for treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent,” Cancer Gene Ther. 16(4):320-328 (2009). [cited by applicant]
Gholami et al., “Novel therapy for anaplastic thyroid carcinoma cells using an oncolytic vaccinia virus carrying the human sodium iodide symporter,” Surgery 150(6):1040-1047 (2011). [cited by applicant]
Gholami et al., “Vaccinia virus GLV-1h153 is a novel agent for detection and effective local control of positive surgical margins for breast cancer,” Breast Cancer Res. 15(2):R26 (2013). [cited by applicant]
Gnant et al, “Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases,” J. Natl. Cancer Inst. 91(20):1744-1750 (1999). [cited by applicant]
Gnant et al., “Regional versus systemic delivery of recombinant vaccinia virus as suicide gene therapy for murine liver metastases,” Ann. Surg. 230(3):352-361 (1999). [cited by applicant]
Gnant et al., “Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of su… [cited by applicant]
Goebel et al., “Appendix to ‘The complete DNA sequence of vaccinia virus,’” Virology 179:517-563 (1990). [cited by applicant]
Goebel et al., “The complete DNA sequence of vaccinia virus,” Virology 179:247-266 (1990). [cited by applicant]
Gocl et al., “Radioiodide imaging and radiovirotherapy of multiple mycloma using VSV(451)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene,” Blood 110(7):2342-2350 (2007). [cited by applicant]
Gómez et al., “Recombinant proteins produced by vaccinia virus vectors can be incorporated within the virion (IMV form) into different compartments,” Arch. Virol. 146:875-892 (2001). [cited by applicant]
Greer III, L and Szalay, A., “Imaging of light emission from the expression of luciferases in living cells and organisms: a review,” Luminescence. 17(1):43-74 (2002). [cited by applicant]
Gribskov et al., “Sigma factors from [cited by applicant]
Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; Computer Analysis of Sequence Data, Part I, 13 pages. [cited by applicant]
Groot-Wassink et al., “Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene,” Hum. Gene Ther. 13:1723-35 (200… [cited by applicant]
Gros et al., “Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency,” Cancer Res. 68: 8928-8937 (2008). [cited by applicant]
Gross-Bellard et al., “Isolation of high-molecular weight DNA from mammalian cells,” Eur. J. Biochem. 36:32-38 (1973). [cited by applicant]
Guo et al., “The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2,” Cancer Res. 65(21):9991-9998 (2005). [cited by applicant]
Guo et al., “Vaccinia as a vector for gene delivery,” Expert Opin. Biol. Ther. 4(6):901-917 (2004). [cited by applicant]
Haddad et al., “Molecular network, pathway, and functional analysis of time-dependent gene changes associated with pancreatic cancer susceptibility to oncolytic vaccinia virotherapy,” Mol. Ther. Oncolytics 3:16008 (2016… [cited by applicant]
Haddad et al., “A novel genetically modified oncolytic vaccinia virus is effective against a wide range of human cancers,” Annals of Surgical Oncology. 3:S665-674 (2012). [cited by applicant]
Haddad et al., “Imaging characteristics, tissue distribution, and spread of a novel oncolytic vaccinia virus carrying the human sodium iodide symporter,” PLoS One. 7(8):e41647 (2012). [cited by applicant]
Haddad et al., “Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of novel vaccinia virus,” J. Translational Med. 9:36 (2011). [cited by applicant]
Haddad et al., “A vaccinia virus encoding the human sodium iodide symporter facilitates long-term image monitoring of virotherapy and targeted radiotherapy of pancreatic cancer,” J. Nucl. Med. 53:1933-1942 (2012). [cited by applicant]
Hall et al., “Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer,… [cited by applicant]
Hammond et al., “A synthetic vaccinia virus promoter with enhanced early and late activity,” J. Virol. Methods 66(1):135-8 (1997). [cited by applicant]
Hanahan et al., “The hallmarks of cancer,” Cell 100:57-70 (2000). [cited by applicant]
Harrington, K., “GL-ONC1 Phase I Trial at Royal Marsden Hospital,” Roche-Genelux Meeting, Penzberg, Germany, Sep. 19, 2011 [poster]. [cited by applicant]
Hawkins, “Oncolytic biotherapy: a novel therapeutic platform,” Lancet Oncol. 3:17-26 (2002). [cited by applicant]
He et al., “A simplified system for generating recombinant adenoviruses,” Proc. Natl. Acad. Sci. U.S.A. 95(5):2509-2514 (1998). [cited by applicant]
He et al., “Effective oncolytic vaccinia therapy for human sarcomas,” J. Surg. Res. 175(2):e53-60 (2012). [cited by applicant]
Henderson and Moss (1999) Smallpox and Vaccinia, Plotkin S, Orenstein W (eds.) Vaccines. W.B. Saunders, Philadelphia, pp. 74-97. [cited by applicant]
Hermiston et al., “Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes,” Cancer Gene Ther. 9:1022-1035 (2002). [cited by applicant]
Hermiston et al., “Genetically based therapeutics for cancer: similarities and contrasts with traditional drug discovery and development,” Mol. Ther. 11(4):496-507 (2005). [cited by applicant]
Hodge et al., “Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules,” Cancer Res. 54(21):5552-5555 (1994). [cited by applicant]
Hofmann et al., “Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice,” Journal of Translational Medicine 12:197 (20… [cited by applicant]
Hofmann et al., “Vaccinia virus GLV-1h237 carrying a Walker A motif mutation of mouse Cdc6 protein enhances human breast tumor therapy in mouse xenografts,” Int. J. Oncol. 38(3):871-878 (2011). [cited by applicant]
Hruby et al., “Vaccinia virus vectors: new strategies for producing recombinant vaccines,” Clin. Micro. Rev. 3:153-170 (1990). [cited by applicant]
Huang et al., “Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis,” Proc. Natl. Acad. Sci. 106(9):3426-3430 (2009). [cited by applicant]
Huang, X. and W. Miller, “A time-efficient, linear-space local similarity algorithm,” Adv. Appl. Math. 12:337-357 (1991). [cited by applicant]
Huang, X., “On global sequence alignment,” Computer Applications in the Biosciences 10(3):227-235 (1994). [cited by applicant]
Hung et al., “Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice,” Gene Ther. 14:20-29 (2007). [cited by applicant]
Ikeda et al., “Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses,” Nat. Med. (8):881-887 (1999). [cited by applicant]